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Ongoing FDA evaluation of approved
endovascular grafts
Dorothy B. Abel, BSBME, Rockville, Md
There have been numerous device integrity and clinical
problems identified with endovascular grafts for aortic an-
eurysm repair, some during clinical investigations and oth-
ers after marketing approval. When significant failures are
identified during clinical studies, enrollment of patients is
suspended. This limits the exposure of patients to the
technology while failure analyses are conducted. Patient
safety is further protected by increased follow-up surveil-
lance for patients with identified device failures. After ap-
proval for marketing, the Food and Drug Administration
(FDA) is less likely to stop the use of a device when new
problems are identified, unless the new problem drastically
alters the safety and effectiveness profile of the device.
Rather, providing current, accurate information regarding
commercially available devices is the primary method used
by the FDA to protect the public health in these circum-
stances.
There are now three endovascular grafts approved for
marketing in the United States, all for the treatment of
abdominal aortic aneurysms. To obtain marketing ap-
proval, a manufacturer must submit data from clinical
studies conducted to demonstrate the safety and effective-
ness of the device. These data undergo extensive review by
FDA medical officers and statisticians prior to presentation
of the information to the FDA advisory panel. In addition,
the manufacturer and selected investigational sites are
audited by the FDA Division of Bioresearch Monitoring
to determine adherence to device regulations and the clin-
ical protocol. Inspectors also compare patient data to the
database for the study to evaluate the accuracy of the
translation.
The extensive clinical data reviewed by the FDA are
summarized in the approved device label. These data are
intended to help clinicians with patient selection and
should provide an indication as to the anticipated perfor-
mance of the device.
The Office of Device Evaluation has implemented the
following mechanism to provide current performance data
to clinicians after the marketing of endovascular grafts.
After approval, manufacturers of such devices are required
to conduct postmarket studies that involve continued
follow-up of patients enrolled in the clinical investiga-
tion. As data have been generated and reported from
these studies, it has become clear that the information in
the original labeling which reflects the clinical trial expe-
rience is not adequate to describe the device performance
after marketing. Accordingly, the FDA now requires that
updated clinical information be communicated to users
of the devices on a yearly basis to ensure that clinicians
have access to the most current data available on device
performance. At a minimum, these updates will include
for the pivotal study cohort a summary of the number of
patients for whom data are available, with the rates of
aneurysm rupture, conversion to surgical repair, aneu-
rysm-related death, all-cause mortality, endoleak, aneu-
rysm enlargement, prosthesis migration, and patency.
Reports of losses of device integrity, reasons for conver-
sion, and summaries of information obtained through
analyses of explanted devices are to be described. Addi-
tional relevant information from commercial experience
within and outside of the United States will also be
included. As with the original labeling, the annual clini-
cal updates will be summaries of the relatively extensive
amount of data reviewed by the FDA.
Through these clinical updates, the FDA facilitates
the ability of clinicians to determine the treatment of
choice for individual patients. This can only be done after
a treatment option becomes available, that is, after FDA
approval of the device. Acknowledgment of these slightly
different roles in ensuring patient welfare clarifies the
value of such regulatory requirements, and in particular
the ongoing role of the FDA in device monitoring after
initial approval.
Other offices in the Center for Devices and Radio-
logical Health have important responsibilities in the
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postmarket surveillance of endovascular grafts, including
the analysis of failures reported by physicians, hospitals,
and manufacturers. To ensure appropriate monitoring at
this stage of the total product life-cycle, it is imperative
that all of the stakeholders in this product area acknowl-
edge and fulfill their responsibilities, not only to report
failures, but also to obtain the most information possi-
ble. For example, much is learned through explant anal-
yses, so physicians should vigorously attempt to obtain
autopsies for patients who die after having been treated
with an endovascular graft. These issues have been dis-
cussed in a recent editorial.1
Probably the greatest lesson that we have learned about
endovascular grafts is that we still have much to learn. By
actively working together and communicating effectively,
we can optimize the treatment of patients with abdominal
aortic aneurysms.
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Comment by the Editors
Updated information on the performance of recently
approved vascular devices is important to properly select
patients for their use and to inform patients of expected
outcomes. The commentary by Abel explains the role of the
FDA in the ongoing evaluation of endovascular grafts for
AAA repair after market approval. In this issue of the
Journal (page 904) we are pleased to provide the first such
device update based on data provided to the FDA by one
manufacturer. We invited the investigators of the underly-
ing Phase II trial to submit this summary article and have
also provided the complete summary from the manufac-
turer, approved by the FDA, as an online-only appendix.
We hope that this mechanism for distributing updated
device information through the Journal will be used in the
future by all manufacturers as they report follow-up data
through the FDA. We also hope that our readers will find
the combination of a peer-reviewed summary article and
the FDA-approved manufacturer’s summary valuable as
they seek to understand the evolving role of new devices in
the management of patients with vascular disease.
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